Novo Nordisk starts Phase 3 trials of inhalable insulin  

Novo Nordisk and US based Aradigm start Phase 3 trials of the inhalable insulin product NN1998

Novo Nordisk and the US based Aradigm Corporation have announced the start of Phase 3 clinical trials of the inhaled insulin product NN1998. The new system converts the liquid insulin formulation into fine aerosolised particles to be delivered locally to the deep lung and thereby to the systemic circulation. The trials are designed to show that the long-term safety and efficacy profile of inhaled human insulin is comparable to that of subcutaneous injections. The study will also monitor for adverse events and overall treatment satisfaction.


One of Denmark's major companies, Novo Nordisk is a world leader in diabetes care. The company employs approximately 17,500 people in 68 countries and markets its products in 179 countries. Based in Hayward, California, Aradigm is working with Novo Nordisk to improve the quality of life for diabetes patients by developing aerosol-based drug delivery alternatives to injectable therapeutics. Aradigm's technology uses liquid drug formulations that are similar to the injectable forms, which may minimise the potential for safety concerns when delivered by the pulmonary route.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×